The randomized, double-blind, standard of care-controlled trial, dubbed BLAST-AHF, assessed three doses of TRV027 plus standard heart failure therapy compared to placebo plus standard therapy in 618 patients with acute heart failure.
TRV027 or placebo was initiated after presentation in the hospital and continued for 48 to 96 hours.
The primary endpoint was a composite of clinically important outcomes including mortality, worsening heart failure, hospital readmission rate, dyspnea and length of hospital stay.
Trevena now plans to focus its efforts on its lead phase 3 oliceridine pain program and its earlier stage programs.
Trevena CEO Maxine Gowen said: "It is always disappointing when an investigational product fails to support a promising hypothesis in a clinical trial.
"We remain confident in our Phase 3 oliceridine program, which has been granted Breakthrough Therapy designation by the FDA, as well as our earlier stage opportunities and platform, and we remain committed to bringing innovative new medicines to patients to treat serious medical needs."
US-based Trevena discovers, develops and aims to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs.